The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform
Kuljit Grewal - One of the best experts on this subject based on the ideXlab platform.
-
Three cases of familial Hairy Cell Leukemia
American journal of hematology, 1993Co-Authors: Mirela Gramatovici, John M. Bennett, Jeffrey G. Hiscock, Kuljit GrewalAbstract:In a 10-year interval, a total of 12 cases of familial Hairy Cell Leukemia have been published. They were noted in first degree relatives, mostly in men. In some instances, when the HLA type was performed, a specific HLA type was found in the studied family, but a different haplotype was seen in other families. It appeared that familial cases of Hairy Cell Leukemia were not associated with a “specific HLA antigen” and other factor(s) such as environmental, or some kind of occupational exposure, were suggested to play a role in the familial occurrence of Hairy Cell Leukemia. We add three more familial Hairy Cell Leukemia cases which are different from other published cases, showing a female predominance. The HLA typing revealed interesting findings. The HLA type shared by case 1 and 3 was A2, A30/31(19), B27, Bw4, Bw6. From these, HLA A2, Bw4, and Bw6 were previously reported (Ward FT, Baker J, Krishnan J, Dow N, Kjobech CH: Cancer 65:319–321, 1990). Case 2, shared with the other two the antigen Bw6. Its specific HLA type was A3 and B7, the type previously reported in a family (Begley CG, Tait B, Crapper RM, Briggs RG, Brodie GN, Mackay IR: Leuk Res 11:1027–1028, 1987). Based on these observations, we may conclude that a “specific HLA type,” A2, Bw4, Bw6 and A3, B7 might have a role in the genetic predisposition for Hairy Cell Leukemia. © 1993 Wiley-Liss, Inc.
Martin J. S. Dyer - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy of Vemurafenib in Hairy-Cell Leukemia
The New England journal of medicine, 2014Co-Authors: Jesvin Samuel, Salvador Macip, Martin J. S. DyerAbstract:The authors report a case of purine analogue–refractory Hairy-Cell Leukemia with biallelic BRAF V600E mutations and a high leukemic burden that was treated successfully with vemurafenib, a BRAF inhibitor.
Mirela Gramatovici - One of the best experts on this subject based on the ideXlab platform.
-
Three cases of familial Hairy Cell Leukemia
American journal of hematology, 1993Co-Authors: Mirela Gramatovici, John M. Bennett, Jeffrey G. Hiscock, Kuljit GrewalAbstract:In a 10-year interval, a total of 12 cases of familial Hairy Cell Leukemia have been published. They were noted in first degree relatives, mostly in men. In some instances, when the HLA type was performed, a specific HLA type was found in the studied family, but a different haplotype was seen in other families. It appeared that familial cases of Hairy Cell Leukemia were not associated with a “specific HLA antigen” and other factor(s) such as environmental, or some kind of occupational exposure, were suggested to play a role in the familial occurrence of Hairy Cell Leukemia. We add three more familial Hairy Cell Leukemia cases which are different from other published cases, showing a female predominance. The HLA typing revealed interesting findings. The HLA type shared by case 1 and 3 was A2, A30/31(19), B27, Bw4, Bw6. From these, HLA A2, Bw4, and Bw6 were previously reported (Ward FT, Baker J, Krishnan J, Dow N, Kjobech CH: Cancer 65:319–321, 1990). Case 2, shared with the other two the antigen Bw6. Its specific HLA type was A3 and B7, the type previously reported in a family (Begley CG, Tait B, Crapper RM, Briggs RG, Brodie GN, Mackay IR: Leuk Res 11:1027–1028, 1987). Based on these observations, we may conclude that a “specific HLA type,” A2, Bw4, Bw6 and A3, B7 might have a role in the genetic predisposition for Hairy Cell Leukemia. © 1993 Wiley-Liss, Inc.
Thorsten Zenz - One of the best experts on this subject based on the ideXlab platform.
-
Hairy Cell Leukemia
Der Internist, 2015Co-Authors: Sascha Dietrich, Mindaugas Andrulis, Thorsten ZenzAbstract:Hairy Cell Leukemia was initially described as a distinct entity in 1958. It is rare B-Cell malignancy characterized by an indolent course. Advances in the treatment and understanding of the biology of Hairy Cell Leukemia have made the disease exquisitely amenable to treatment. This review summarizes the present understanding of Hairy Cell Leukemia with a particular focus on the development of novel and targeted approaches to treatment.
-
BRAF inhibition in refractory Hairy-Cell Leukemia.
The New England journal of medicine, 2012Co-Authors: Sascha Dietrich, Mindaugas Andrulis, Hanno Glimm, Christof Von Kalle, Thorsten ZenzAbstract:The authors report a dramatic response to vemurafenib in a patient with Hairy-Cell Leukemia refractory to nucleosides and rituximab.
Kanti R. Rai - One of the best experts on this subject based on the ideXlab platform.
-
Interferon in the treatment of Hairy-Cell Leukemia.
Best practice & research. Clinical haematology, 2003Co-Authors: Shahid Ahmed, Kanti R. RaiAbstract:The introduction of alpha interferon in 1984 initiated a new and exciting turnaround in the treatment of Hairy-Cell Leukemia. Until that time splenectomy was the only known effective therapy for this disease. Interferon proved to benefit Hairy-Cell Leukemia patients with active disease, whether or not they had undergone prior splenectomy. However, most interferon-induced responses were partial and were of relatively short duration. Purine analogues such as cladribine and pentostatin have since been found to be more effective than alpha interferon and, therefore, have now replaced interferon as first-line therapy for Hairy-Cell Leukemia. At the present time, interferon has a relatively limited role in the treatment of Hairy-Cell Leukemia and it is reserved for a group of selected patients who have failed nucleoside analogue therapy. In this chapter, we discuss the efficacy of interferon and its response duration, toxicity and possible mechanism of action in patients with Hairy-Cell Leukemia.
